Hydroxychloroquine is effective in oral lichen planus: A multicenter, randomized, controlled trial

Abstract

AbstractObjectivesThis study was aimed to evaluate the safety and benefit of short‐term application of hydroxychloroquine in the management of atrophic/erosive/ulcerative oral lichen planus (OLP).MethodsThis multicenter, randomized, controlled, evaluator‐blinded, prospective clinical trial was performed from October 1, 2019, to September 1, 2022. A total of 99 patients were randomized to receive systemic use of hydroxychloroquine (n = 50), or topical use of 0.05% dexamethasone (n = 49) for 4 weeks. The response to both treatment modalities was evaluated according to reticulation, hyperemic, and ulceration (RHU) score and visual analog scale (VAS) score.ResultsAfter 4 weeks of medication, both groups showed substantial reduction in RHU and VAS score (p < 0.05). In hydroxychloroquine group, the average of RHU score was reduced from 10.60 to 7.68 (dropped 27.49%), and the average of VAS score was reduced from 3.74 to 2.47 (dropped 34.09%). There were no differences between the two groups in reduction of RHU score and VAS score (p > 0.05). Single factor analysis found hyperemic area (p = 0.019) and erosive/ulcerative area (p = 0.024) had impacts on drug efficacy of hydroxychloroquine, and logistic regression revealed that no factors (p > 0.05) influenced its efficacy.ConclusionThese findings indicate hydroxychloroquine is a safe and effective agent in treating atrophic/erosive/ulcerative OLP.